Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus. Intervention included randomization to 25 mg of hydrochlorothiazide or 100 mg of atenolol monotherapy followed by their combination. Fasting glucose, insulin, triglycerides, high-density lipoprotein cholesterol, and uric acid levels were measured at baseline and after monotherapy and combination therapy. Outcomes included new occurrence of and predictors for new cases of glucose ≥100 mg/dL (impaired fasting glucose), triglyceride ≥150 mg/dL, high-density lipoprotein ≤40 mg/dL for men or ≤50 mg/dL for women, or new-onset diabetes mellitus according to the presence or absence of abdominal obesity. Abdominal obesity was present in 167 (58%) of 395 patients. Regardless of strategy, in those with abdominal obesity, 20% had impaired fasting glucose at baseline compared with 40% at the end of study ( P <0.0001). Proportion with triglycerides ≥150 mg/dL increased from 33% at baseline to 46% at the end of study ( P <0.01). New-onset diabetes mellitus occurred in 13 patients (6%) with and in 4 patients (2%) without abdominal obesity. Baseline levels of glucose, triglyceride, and high-density lipoprotein predicted adverse outcomes, and predictors for new-onset diabetes mellitus after monotherapy in those with abdominal obesity included hydrochlorothiazide strategy (odds ratio: 46.91 [95% CI: 2.55 to 862.40]), female sex (odds ratio: 31.37 [95% CI: 2.10 to 468.99]), and uric acid (odds ratio: 3.19 [95% CI: 1.35 to 7.52]). Development of adverse metabolic effect, including new-onset diabetes mellitus associated with short-term exposure to hydrochlorothiazide and atenolol was more common in those with abdominal obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016
Obesity as a cardiovascular risk factor
Sowers, J. R. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.012 · Cited by 584
Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled
BRAMLAGE, P., PITTROW, D., WITTCHEN, H., KIRCH, W., BOEHLER, S., LEHNERT, H., HOEFLER, M., UNGER, T., & SHARMA, A. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.05.017 · Cited by 328
Cited by
Shariq, O. A., & McKenzie, T. J. (2020) · Gland Surgery · doi:10.21037/gs.2019.12.03 · Cited by 359
Type 2 Diabetes Mellitus and Hypertension
Lastra, G., Syed, S., Kurukulasuriya, L. R., Manrique, C., & Sowers, J. R. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.005 · Cited by 307
“Thiazide diuretics do have some significant negative metabolic effects, in particular impaired glycemic control by impairment of insulin secretion and insulin sensitivity (97,98).”
Bamgboye, A. O., Oni, I. O., & Collier, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03051-3 · Cited by 48
First-line diuretics versus other classes of antihypertensive drugs for hypertension
Reinhart, M., Puil, L., Salzwedel, D. M., & Wright, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008161.pub3 · Cited by 38
Jain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32
“A study by Cooper-DeHoff has demonstrated that new-onset diabetes caused by hydrochlo-rothiazide may occur at 9–18 weeks of initiation [60].”
Background
Metadata
- Authors
- Cooper-DeHoff, R. M., Wen, S., Beitelshees, A. L., Zineh, I., Gums, J. G., Turner, S. T., Gong, Y., Hall, K., Parekh, V., Chapman, A. B., Boerwinkle, E., & Johnson, J. A.
- Venue
- Hypertension
- Published
- 2010-01
- Volume
- 55
- Issue
- 1
- Pages
- 61-68
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2146798669
- Cited by
- 80
- References
- 4
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications. https://app.cochat.ai/papers/10.1161/hypertensionaha.109.139592
- The paper
- Cooper-DeHoff, R. M., Wen, S., Beitelshees, A. L., Zineh, I., Gums, J. G., Turner, S. T., Gong, Y., Hall, K., Parekh, V., Chapman, A. B., Boerwinkle, E., & Johnson, J. A. (2010). Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications. Hypertension. https://doi.org/10.1161/hypertensionaha.109.139592
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.